Our Approach
At Pulmongene, we utilize advanced preclinical models and cutting-edge translational research with patient-derived systems to identify and target key profibrotic pathways that drive IPF and other fibrotic lung diseases.
About IPF
Pulmonary fibrosis is a severe and progressive condition in which healthy lung tissue is gradually replaced by scar tissue. This process disrupts lung structure, impairs gas exchange, and can ultimately lead to respiratory failure and death.
Idiopathic pulmonary fibrosis (IPF) is a particularly aggressive form of pulmonary fibrosis, with a median survival time of only 3-5 years. IPF is characterized by dysfunctional epithelial repair and excessive production of profibrotic factors, which activate fibroblasts and drive excessive scar formation.